Losers

The 2012 Academy Awards In Charts And Data

Source: http://www.businessinsider.com/the-oscars-for-quants-the-2012-academy-awards-in-charts-and-data-2012-2


oscar charts

Sure, The Artist did well at the Academy Awards. But what does that really mean, statistically?

As usual, our friends at AddThis, a company that provides social media sharing tools for web publishers, tracked their network of 11 million sites and 1.2 billion unique users per month to find out which Oscar events really drove chatter among consumers.

The data show that the real Oscar winners were the iPad, Pinterest, Sacha Baron Cohen and Twitter. Losers included Ryan Seacrest, Facebook and Billy Crystal.

 

This was the background chatter in the weeks prior to the Oscars. Note that ‘Hugo’ dominates.

Demian Bichir peaked when he was nominated for a SAG award for ‘Better Life.’ But interest faded. More people were interested in George Clooney than Jean Dujardin of ‘The Artist’ in the week before the Oscars.

Prior to the show, the people’s choice for Best Actress was Viola Davis, not Meryl Streep.

See the rest of the story at Business Insider

Please follow Advertising on Twitter and Facebook.

See Also:



Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Tuesday, February 28th, 2012 news No Comments

Here Are The Winners And Losers

Source: http://www.businessinsider.com/super-bowl-ads-2012-here-are-the-winners-and-losers-2012-2


clint eastwood

There’s fascinating disconnect between which advertisers the media thinks did well on last night’s Super Bowl and what the research says was effective.

To hear the business press tell it, Clint Eastwood’s “Halftime in America” spot rocked the house. It was indeed a great spot from a creative point of view.

But it didn’t even show up in the Ace Metrix Top 10. Ace Metrix measures a panel of 500 consumers who watch ads and rate them for effectiveness. That research says Doritos’ sling baby ad won the night.

It was also a big night for dogs. Volkswagen’s much anticipated follow-up to its little Darth Vader spot from last year used an obese dog getting in shape to gets its revenge on a VW it wanted to chase down the street (and then somehow ended up in the Star Wars cantina scene).

Skechers used a dog — Mr. Quiggly — in a greyhound race.

As did Bud Light, whose appeal with Weego, a rescue dog, was heartwarming.

So did Doritos, in another comedic appeal revolving around the whole Dogs v. Cats war.

There weren’t any total disasters — last year both Groupon and HomeAway had to apologize for their ads — but there were some failures in the sense that clients ads bored people or went unnoticed.

Chase ran an ad that for the life of me I can’t recall even though I am paid to remember these things. And TaxACT’s ad, featuring a kid who urinates in a swmming pool, was disgusting.

Later today — much later — we’ll take a look at how B.I.’s readers judged the ads with the results of our Super Bowl ad readers’ poll. Vote early, and often!

Please follow Advertising on Twitter and Facebook.

Join the conversation about this story »

See Also:



Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Monday, February 6th, 2012 news No Comments

The World’s Largest Blockbuster Drug Just Went Generic — Here Are The Winners And Losers (PFE, WPI, ABC, TEVA, MRK, MYL, CVS, WAG)

Source: http://www.businessinsider.com/the-nations-largest-blockbuster-drug-just-went-generic-2011-11


pfizerap1017

With the expiration of Pfizer’s patent exclusivity on Lipitor, the nation’s top selling drug will go generic and see a market share split that will force manufacturers into a share race.

Lipitor, a cholesterol drug that reduces cholesterol, came to market in 1997 and ultimately peaked with sales of $13 billion. Last year, it contributed $10.7 billion in revenue to Pfizer.

Analysts remain divided over how much market share Pfizer will be able to hold on to. The company is aggressively discounting the drug through a program to entice patients to remain on Lipitor. Over the coming 180 days, Watson Pharmaceuticals and Ranbaxy Laboratories of India will enter the market.

Eight Citi analysts poured over data and see Pfizer retaining 40-50% of market share over the next half year. Delays out of Ranbaxy, which were prompted by U.S. regulatory bans over questionable quality concerns, will aid Pfizer.

But after the 180 days, when another round of pharmaceuticals like Teva and Aurobindo are allowed entry, the cost of Lipitor will drop to “pennies a day,” Citi analyst John Boris writes.

However, most of Lipitor’s decline has already been priced into Pfizer stock over the past year. “We maintain our Pfizer 4Q11E/2012E Lipitor sales/EPS contribution at $930M/$640M,” Boris continues. That represents a Lipitor sales contribution of 14-18% of fourth EPS, before falling to just 2% of earnings in 2012.

The largest to benefit from the change may be drug stores like CVS and Walgreens, which may see an uptick as more patients can afford to take cholesterol medications, even as average drug prices decline.

“In addition, we believe that the drugstores will be able to generate stronger gross profit dollars as the average gross margin for generic drugs is generally 50 to 60%, while the average gross margin for branded drugs is approximately 20%,” Boris says. 

Meanwhile, Pfizer is betting its name on smaller blockbusters in other drug categories to contribute $4 billion in new revenue by 2014 as it re-emerges in a world post-Lipitor.

Please follow Money Game on Twitter and Facebook.

Join the conversation about this story »

See Also:




drag2share – drag and drop RSS news items on your email contacts to share (click SEE DEMO)

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Wednesday, November 30th, 2011 news No Comments

Dr. Augustine Fou is Digital Consigliere to marketing executives, advising them on digital strategy and Unified Marketing(tm). Dr Fou has over 17 years of in-the-trenches, hands-on experience, which enables him to provide objective, in-depth assessments of their current marketing programs and recommendations for improving business impact and ROI using digital insights.

Augustine Fou portrait
http://twitter.com/acfou
Send Tips: tips@go-digital.net
Digital Strategy Consulting
Dr. Augustine Fou LinkedIn Bio
Digital Marketing Slideshares
The Grand Unified Theory of Marketing